San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, August 18, 2015
AmpliPhi Biosciences Corporation (OTCQB: APHBD), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its shares of common stock have been approved for listing on the NYSE MKT, subject to continued satisfaction of listing requirements. The company anticipates its common stock will begin trading on the NYSE MKT under the ticker APHB on August 21, 2015.
“We welcome AmpliPhi Biosciences to the NYSE MKT family of listed companies and look forward to a long term partnership,” said Garvis Toler, Global Head of Capital Markets, New York Stock Exchange. “AmpliPhi is joining other well-known biotech companies taking advantage of the NYSE’s innovative, leading market model for listing and trading their shares.”
“The NYSE MKT listing represents a key milestone for AmpliPhi on our mission to develop novel bacteriophage-based treatments to combat the growing global threat posed by antibiotic-resistant bacteria, and extend our leadership position in this competitive space,” said M. Scott Salka, CEO of AmpliPhi. “We expect that trading our shares on the NYSE will directly benefit our shareholders both by improving the liquidity of their investment and enhancing our corporate profile amongst potential investors and prospective partners.”
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation (OTCQB: APHBD) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. The Company’s product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE:XON), the U.S. Army, The Royal Brompton Clinic in London and The University of Leicester, UK to rapidly advance bacteriophage-based therapies.
For more information, visit www.ampliphibio.com.
Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.
Forward Looking Statements
Statements in this press release about AmpliPhi’s NYSE MKT listing, trading liquidity of AmpliPhi stock, the potential use of bacteriophages to treat bacterial infections, including infections in biofilms and infections that do not respond to antibiotics, and the development of bacteriophage-based therapies are forward looking statements subject to risks and uncertainties, including without limitation the risk that the Company may not be able to raise additional capital on acceptable terms, if at all, that the Company will not be able to successfully manufacture sufficient quantities of products to conduct clinical trials or commercialize products in a timely manner or at all, that AmpliPhi may not commence clinical trials or complete IND-enabling studies as expected, that the Company’s clinical trials will not be successful, that further development of the Company’s products will require extensive and expensive nonclinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to AmpliPhi’s business in general, see AmpliPhi’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as amended, filed with the Securities and Exchange Commission (SEC) on April 15, 2015.